Dissecting Therapeutic Resistance to ERK Inhibition Rat Wild Type SCH772984 in complex with (3R)-1-(2-oxo-2-{4-[4-(pyrimidin-2-yl)phenyl]piperazin-1-yl}ethyl)-N-[3-(pyridin-4-yl)-2H-indazol-5-yl]pyrrolidine-3-carboxamide

Dissecting Therapeutic Resistance to ERK Inhibition.

MAPK 1,ERT1,Extracellular signal-regulated kinase 2,ERK-2,MAP kinase isoform p42,p42-MAPK,Mitogen-activated protein kinase 2,MAPK 2

0.1M MES, PH 6.4, 2.0M AMMONIUM SULFATE, 5% PEG 400, 0.5% DMSO, 1% GLYEROL, 0.0005M OLOMOUCINE, 10 DAY SOAK WITH NEW COMPOUND at 500 MICROMOLAR CONCENTRATION

Mitogen-activated protein kinase 1 (E.C.2.7.11.24)

TRANSFERASE, SERINE/THREONINE-PROTEIN KINASE, MAP KINASE, TRANSFERASE-TRANSFERASE INHIBITOR COMPLEX